Search Results Label

Seqirus has been on the front line of pandemic preparedness for more than a century. Learn more about our rapid vaccine production capabilities.

https://www.seqirus.us/expertise/influenza/pandemic-response-solutions

Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.

https://www.seqirus.us/expertise

Seqirus appoints Roberta Duncan as new program lead to drive technology advancement. Accelerates development of sa-mRNA vaccine candidates for seasonal and pandemic influenza.

https://www.seqirus.us/news/seqirus-invests-in-self-amplifying-messenger-rna-technology

Seqirus Presents New Data at ESWI 2020 Demonstrating Safety and Immunogenicity of Adjuvanted, Cell-Based Pandemic Influenza A (H5N1) Vaccine

https://www.seqirus.us/news/seqirus-presents-new-data-at-eswi-2020-demonstrating-safety-and-immunogenicity

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.us/news/seqirus-announces-us-fda-approval-of-pandemic-influenza-vaccine

Seqirus announced today that the accelerated development of cell-based manufacturing technology at its manufacturing facility in Holly Springs, North Carolina, has delivered a four-fold increase in seasonal influenza vaccine output in just two years, strengthening the United States’ capacity to respond to pandemic threats.

https://www.seqirus.us/news/seqirus-announces-major-advances-in-pandemic-preparedness

Findings from a new observational safety study conducted in the U.S. found no unexpected adverse pregnancy outcomes in pregnant people who were vaccinated with the cell-based quadrivalent seasonal influenza vaccine during pregnancy.

https://www.seqirus.us/news/safety-data-seasonal-pregnancy

The company is prepared to meet the record levels of demand seen during the 2020/21 influenza season amidst the ongoing COVID-19 pandemic

https://www.seqirus.us/news/first-shipment-2021-22

New Phase 3 Clinical Data Supporting Use of Cell-Based Seasonal Influenza Vaccine in Children Six Months Through <4 Years of Age

https://www.seqirus.us/news/data-supports-cell-based-flu-vaccine-in-children

Seqirus, as a member of the CSL group, is bound by CSL's Code of Responsible Business Practice. Access our annual financial and diversity disclosures.

https://www.seqirus.us/our-company/corporate-responsibility/disclosures